The Comparison between Co-Administration of Surfactant and Fentanyl with Administration of Surfactant in Neonatal with Respiratory Distress Syndrome

Respiratory distress syndrome is one of the most common diseases in premature infants and one of the leading causes of death in premature infants. Treatment is the administration of exogenous surfactant, which is administered intramuscularly, which is an invasive and painful procedure. The aim of this study was to compare the effect of concomitant administration of surfactant and fentanyl with the administration of surfactant in reducing the administration of repeated doses of surfactant in infants with respiratory distress syndrome.

This study was performed by a step-by-step clinical trial with a blind historical comparison on 30 infants with respiratory distress syndrome hospitalized in Bent Al-Huda Hospital with a mean and standard deviation of 32/8 ± 2/24 years. Patients were divided into intervention and control groups. In the control group, surfactant patients received only and in the intervention group surfactant and fentanyl. Data analysis was performed by SPSS software, version 19, using statistical tests. A significant level of 0/05 was considered.

In this study, there was no significant relationship between fentanyl administration and surfactant compared with surfactant administration only in reducing the frequency of repeated doses of surfactant, however, the number of infants requiring repeated dose of surfactant in infants receiving fentanyl was lower. Significant correlation was found between fentanyl administration and neonatal pain.

It is recommended that fentanyl be used for pain relief when administering surfactant by intra-chip tubing in infants with respiratory distress syndrome.